Comparing Hyperoxygenated Fatty Acids and Hydrocolloid Dressings for Preventing Pressure Ulcers in Critically Ill Patients in Prone Position

What this Trial Is About

Researchers are evaluating two different skin treatments to prevent pressure ulcers in critically ill patients placed in the prone position, a common practice especially during the COVID-19 pandemic. This randomized clinical trial compares the use of Hyperoxygenated Fatty Acids HOFA with Hydrocolloid Dressings HCD to see which is more effective in reducing pressure ulcers and related complications in intensive care units across multiple hospitals. Participants will be randomly assigned to one of two groups one receiving HOFA applied to pressure-prone areas, and the other using hydrocolloid dressings for protection. Care will follow strict protocols, and the assigned treatment will continue throughout any additional prone positioning sessions required during the ICU stay. The study includes a pilot phase and ongoing data collection from various hospitals to standardize procedures and ensure consistent care. Patients will be monitored throughout their ICU stay, with data collected before, during, and after each prone positioning session, as well as 24 hours afterward. Researchers will assess the occurrence, location, size, and severity of pressure ulcers, along with other clinical and treatment-related variables. Data will be securely recorded and analyzed to compare outcomes between the two groups, with safety monitored and follow-up conducted as needed. The study is expected to continue until enough participants have been enrolled and data collected.

Efficacy of HOFA Versus Hydrocolloid Dressings in the Prevention of PUs in Critically Ill Prone Patients